IXHL — Incannex Healthcare Share Price
Last trade - 00:00- $35.71m
- $26.41m
- $0.93m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.93 | ||
| Price to Tang. Book | 3.93 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 60 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -93.41% | ||
| Return on Equity | -34.4% | ||
| Operating Margin | -1451.32% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0 | 0.55 | 1.47 | 0.57 | 0.93 | 0.05 | n/a | 3.38% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.
Directors
- Troy Valentine NEC
- Joel Latham CEO
- Mark Bleakley CFO
- Alistair Blake CTO
- Graham Howard GMG
- Sudhanshu Agarwal OTH
- Glenn Fowles SEC
- Peter Widdows NED
- Last Annual
- June 30th, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- July 5th, 2023
- Public Since
- March 18th, 2022
- No. of Shareholders
- 12,709
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 15,873,113
- Address
- 18 East 50th Street, 5th Floor, NEW YORK, 10022
- Web
- Phone
- Auditors
- PKF Brisbane Audit
Upcoming Events for IXHL
Similar to IXHL
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
Alimera Sciences
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
FAQ
As of Today at 21:17 UTC, shares in Incannex Healthcare are trading at $3.50. This share price information is delayed by 15 minutes.
Shares in Incannex Healthcare last closed at $3.50 and the price had moved by -52.96% over the past 365 days. In terms of relative price strength the Incannex Healthcare share price has underperformed the S&P500 Index by -62.57% over the past year.
There is no consensus recommendation for this security.
Incannex Healthcare does not currently pay a dividend.
Incannex Healthcare does not currently pay a dividend.
Incannex Healthcare does not currently pay a dividend.
To buy shares in Incannex Healthcare you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.50, shares in Incannex Healthcare had a market capitalisation of $55.56m.
Here are the trading details for Incannex Healthcare:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: IXHL
Based on an overall assessment of its quality, value and momentum Incannex Healthcare is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Incannex Healthcare. Over the past six months, its share price has underperformed the S&P500 Index by -22.18%.
As of the last closing price of $3.50, shares in Incannex Healthcare were trading -10.01% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Incannex Healthcare PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Incannex Healthcare's management team is headed by:
- Troy Valentine - NEC
- Joel Latham - CEO
- Mark Bleakley - CFO
- Alistair Blake - CTO
- Graham Howard - GMG
- Sudhanshu Agarwal - OTH
- Glenn Fowles - SEC
- Peter Widdows - NED